drugset / Trial / NCT06746688
A First-in-human, Clinical Trial Assessing the Safety of ES2B-C001-S01 With or Without [Adjuvant] in Patients With HER2-expressing Metastatic Breast Cancer.
Phase 1
Recruiting
40 enrolled
ExpreS2ion Biotechnologies
Gouya Insights · collabKKS MedUni Vienna · collabVelaLabs · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
The trial is a first-in-human, phase I, open-label, dose-escalating trial to assess the safety and tolerability of ES2B-C001 combined with or without \[adjuvant\], in patients with human epidermal growth factor receptor 2 (HER2) expressing metastatic breast cancer.
Timeline
- Start
- 2025-06-03
- Primary completion
- 2026-12
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ES2B-C001 | Unknown | 50 ug | — |
| Subject | ES2B-C001 | Unknown | 150 ug | — |
| Subject | ES2B-C001 | Unknown | 450 ug | — |